SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as investors react to escalating US-China trade tensions and await insights from upcoming bank earnings and a speech from Fed Chair Powell. Community chatter reflects concerns about market volatility, potential pullbacks, and the impact of Trump's trade policies. Some traders are anticipating a buying opportunity amidst the uncertainty, while others are bracing for a deeper correction.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending amid discussions about market manipulation and potential trade war impacts, with community members debating whether recent price dips represent buying opportunities or signs of a larger correction. Concerns about leveraged positions and insider activity are also circulating, while some analysts maintain a bullish long-term outlook. The digital asset's performance is being closely watched in relation to traditional markets and geopolitical developments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to renewed US-China trade war concerns sparked by China's sanctions on a Korean shipbuilder and the potential for further tariff escalations, creating market volatility. Community discussions revolve around whether these movements are news-driven rather than technical, and whether Trump's actions will reverse the current downturn. Overall sentiment seems mixed, with some expecting a bounce while others anticipate further drawdowns.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst ($BCRX) is trending amid news of its acquisition of Astria Therapeutics ($ATXS) to bolster its HAE portfolio, a move that has sparked mixed reactions. While some investors see long-term growth potential, others express concerns about the acquisition's cost and potential impact on profitability, leading to active discussions about the company's future direction and valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

$CRML is trending as the U.S. aims to secure rare earth elements and reduce reliance on China, sparking community interest in resource independence and potential government support. Discussions revolve around the company's assets in Greenland and the potential for significant growth in a sector deemed critical for national security. Some traders are pointing to a large move in a related ticker, $CLIK, as a reason for caution.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as discussions revolve around its potential to become a key domestic antimony supplier, especially after the U.S. Department of War awarded funds to Alaska Range Resources (ARR), its subsidiary, to secure the antimony supply chain. The community is focused on the company's unique position with both antimony and gold prospects, viewing it as undervalued compared to other rare earth plays. Some investors express enthusiasm about NVA's long-term growth potential given its Alaskan mining assets.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending due to discussions around potential short squeezes and high volatility, with traders actively speculating on entry and exit points. Community members are weighing in on the stock's potential for a significant run-up, while others highlight concerns about past dilutions and reverse splits. The stock's low float and presence in the recycling and critical metals space are also contributing to the heightened interest.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is trending due to progress in developing GaN and SiC power devices for NVIDIA's next-gen AI factory architecture, specifically supporting the 800 VDC power architecture. The community is focused on the potential for increased efficiency and power density in AI data centers, with some speculating about a possible short squeeze given the stock's high short interest. Some traders are drawing parallels to other AI-related stocks and anticipating further upside.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending following the release of its Q3 2025 earnings, which revealed profits boosted by investment banking and trading. Community members are actively discussing the better-than-expected revenue and trading results, while also pointing out a net reserve build. Some are speculating on the potential impact of the earnings on the broader market.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending due to a premarket surge, fueled by retail trader interest in PMGC Holdings' shift towards biotech and industrial sectors. Community discussions revolve around the stock's low float and potential for a squeeze, while some traders are pointing to possible overextension. The stock's volatility and previous reverse splits are also being discussed.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Equity

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.


Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a late-stage study in adults and adolescents with atopic dermatitis (AD).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-09-04-05-00-00-3144170">study</a> enrolled 601 adults and adolescents aged 12 years and older with moderate-to-severe AD. Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24. Furthermore, a progressive increase in efficacy was observed during the treatment period in patients who were dosed every four weeks as well as in those who were dosed every 12 weeks, the company said.The most common treatment-emergent adverse events, such as upper respiratory tract infection, were more common in the placebo arm compared to the Amlitelimab-treated arms of the study, it said.Shares of the company, however, traded 9% lower in the premarket session at the time of writing.According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-sheds-13-billion-value-weak-trial-results-eczema-drug-2025-09-04/">report</a>, Jefferies analysts opined that the trial results fell short of those from an earlier trial and of rival biologic drugs. However, the drug's safety profile and convenient 12-week dosing regimen could still support its use.JPMorgan, meanwhile, noted that the data confirmed that Amlitelimab is less effective than Sanofi’s approved drug Dupixent, Reuters added. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:578/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_7_50_44_AM_png_2f5aa98d10.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="578" height="61"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:51 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>Sanofi’s Dupixent is approved to treat atopic dermatitis in addition to asthma, chronic spontaneous urticaria, and other diseases. In the second quarter, Dupixent sales increased by 21.1% to €3.8 billion ($4.43 billion), and the company was expecting Amlitelimab to complement the blockbuster drug.The firm now looks forward to sharing additional late-stage results from the clinical development program of Amlitelimab in atopic dermatitis, said Houman Ashrafian, Executive Vice President, Head of Research &amp; Development at Sanofi.SNY stock is up 3% this year but down approximately 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/fda-says-no-advisory-commitee-meeting-required-for-aquestive-oral-epinephrine-film/chwd20pRdYB">FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: €1= $1.17

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More

Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically meaningful efficacy in skin clearance and disease severity compared to placebo at week 24, the company said. 

A Delaware federal judge on Friday reportedly said that Novartis (NVS) cannot block India-based drugmaker MSN Pharmaceuticals from launching a generic version of its heart failure drug Entresto before its patent expires late next year.The judge rejected Novartis’ argument that the generic would infringe on one of the company’s patents, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/novartis-loses-bid-block-us-entresto-generic-through-2026-2025-07-11/">reported</a>. U.S. District Judge Richard Andrews also denied Novartis’ request to block the generic from launching until after the patent expires in November 2026.NYSE-listed shares of <a href="https://stocktwits.com/symbol/NVS">Novartis</a> were trading 2% lower at the time of writing.Novartis told Reuters in a statement that it plans to appeal.The company told the court in a filing on Friday that MSN may receive the U.S. Food and Drug Administration’s approval for the generic as soon as July 16 and launch it soon after, cutting into the market for Entresto.Entresto is a prescription medicine used to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization. It was Novartis’s best-selling brand in the first quarter.The company reported $2.26 billion in net sales for the drug, marking a growth of 22% at constant currency. The drug, in fact, accounted for over 17% of the company’s overall net sales in the period.The company said in April that the drug had sustained, robust, demand-led growth globally in the quarter, including in China and Japan, with increased penetration in hypertension.On Stocktwits, retail sentiment around Novartis remained unmoved in the ‘neutral’ territory over the past 24 hours while message volume stayed unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_2_12_01_PM_png_5d097b2dd4.webp" alt="NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>NVS's Sentiment Meter and Message Volume as of 2:10 p.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 25% this year and by about 10% over the past 12 months.Read Next: <a target="_blank" rel="noopener noreferrer nofollow" href="https://CMS’s Initial Proposal To Cover Renal Denervation A Win For Medtronic, Says Analysts">CEL-SCI Stock Soars On Imminent Partnership With Saudi Arabian Pharma Company For Cancer Drug: Retail’s Thrilled</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Fails To Block Heart Failure Drug’s Generic From Launching Through 2026: Report

Novartis’ heart failure drug Entresto accounted for over 17% of the company’s overall net sales in the first quarter of 2025.

Novartis (NVS) on Tuesday said that Swiss authorities have approved its Coartem Baby as the first malaria medicine for newborns and young infants.<a href="https://stocktwits.com/symbol/NVS">Novartis</a> developed the treatment, also known as Riamet Baby in some geographies, in collaboration with Medicines for Malaria Venture (MMV).The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-receives-approval-first-malaria-medicine-newborn-babies-and-young-infants">said</a> that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. &nbsp;Malaria is a life-threatening disease caused by a parasite and spread to humans by some types of mosquitoes. Novartis cited WHO data and noted that there were 263 million cases of malaria and 597,000 deaths in 2023, almost all of them in Africa.&nbsp;The company said it intends to introduce the infant-friendly treatment on a largely not-for-profit basis where malaria is endemic. According to Novartis, some 30 million babies are born in areas of malaria risk in Africa every year.The new approval is for the treatment of malaria in infants weighing between 2kg and 5kg. Novartis said there were no approved malaria treatments for infants weighing less than 4.5kg until now, leaving a treatment gap. Furthermore, malaria vaccines are also not approved for the youngest babies, the company noted.The pediatric formulation of the treatment is dissolvable, including in breast milk, and has a sweet cherry flavor to make it easier to administer.“The approval of Coartem Baby provides a necessary medicine with an optimized dose to treat an otherwise neglected group of patients and offers a valuable addition to the antimalarial toolbox,” CEO of MMV Martin Fitchet said.On Stocktwits, retail sentiment around Novartis is trending in the “bullish” territory, coupled with “high” message volume.<figure class="image"><img style="aspect-ratio:1250/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_7_32_02_AM_png_2a581d344f.webp" alt="NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits" width="1250" height="130"><figcaption>NVS's Sentiment Meter and Message Volume as of 7:30 a.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by about 26% this year and by 13% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/musk-ally-isaacman-reacts-to-trump-s-political-jabs-says-nasa-without-a-confirmed-leader-not-ideal-for-america/chFvNyDR5g4">Musk Ally Isaacman Reacts To Trump’s Political Jabs, Says NASA Without A Confirmed Leader ‘Not Ideal For... America’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis Gets Swiss Authority Nod For First Malaria Drug In Newborns, Young Infants

The company said that it now expects rapid approval for the treatment in eight African countries, including Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Uganda, and Tanzania. 

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis failed to meet its primary goal of sustained remission. &nbsp;Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper in the trial. The drug, however, did not demonstrate a statistically significant improvement in sustained remission at week 52 compared to placebo.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-gcaptain-study-cosentyx-giant-cell-arteritis-gca">said</a> that it will share a full evaluation of the trial data at a later date.Shares of Novartis were trading 1% lower in the pre-market session.Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels. GCA primarily affects people over 50 years of age and has the potential to cause irreversible vision loss and life-threatening aortic aneurysms.Cosentyx, launched in 2015, is already approved for use in adults with multiple conditions such as psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.It is also approved in pediatric patients with moderate to severe plaque psoriasis, enthesitis-related arthritis, and juvenile psoriatic arthritis.In the first quarter of 2025, Cosentyx brought in $1,534 million in net sales, marking a growth of 18% at constant currency, as sales grew mainly in the U.S., emerging markets, and Europe.Cosentyx, in fact, accounted for about 12% of the company’s overall net sales in the quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_03_082008_png_2cf306955c.webp" alt="NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits" width="627" height="57"><figcaption>NVS's Sentiment Meter and Message Volume as of 8:20 a.m. ET on July 3, 2025 | Source: Stocktwits</figcaption></figure>NVS stock is up by over 27% this year and by about 16% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-targets-1.5-billion-from-bond-sale-linked-to-health-arm/chFjAFkRcmI">Alibaba Targets $1.5B From Bond Sale Linked To Health Arm: Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

Danish drugmaker Novo Nordisk (NVO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348">announced</a> on Thursday that it plans to initiate a late-stage development program with its experimental drug Amycretin for adults with obesity or those who are overweight, starting in the first quarter of 2026.Shares of NVO traded 3% higher on Thursday.The decision to advance the study of Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.Amycretin is a single molecule that operates as both GLP-1 receptor agonist and amylin receptor agonist.While GLP-1 receptor agonists work by mimicking the natural hormone GLP-1, Amylin receptor agonists mimic the effects of the natural hormone amylin, reducing appetite. The drug is developed for subcutaneous and oral administration.The company’s popular weight-loss drug Wegovy’s active component is Semaglutide, another GLP-1 receptor agonist.In the first quarter, Wegovy experienced an 85% increase in sales to DKK 17.36 billion ($2.69 billion), while the company’s overall sales within its obesity care segment grew 67% to DKK 18.42 billion.However, last month, the company said that Lars Fruergaard Jørgensen will <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">step down</a> as CEO as per a mutual agreement with the Novo Nordisk board.The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen by about 8% this year and by about 44% over the past 12 months.On Stocktwits, retail sentiment around Novo Nordisk stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_2_12_25_PM_png_81063cab85.webp" alt="Screenshot 2025-06-12 at 2.12.25 PM.png" width="628" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/google-cloud-teams-up-with-databricks-to-scale-gemini-enterprise-adoption/chlgdNHRRGd">Google Cloud Teams Up With Databricks To Scale Gemini Enterprise Adoption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 DKK= 0.16 USD)

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Mesoblast (MESO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investorsmedia.mesoblast.com/static-files/45831458-f1fc-48e1-ae2c-ede16ee03af2">said</a> on Thursday it is awaiting the final minutes from the U.S. Food and Drug Administration (FDA) to provide timelines for potential filing for its late-stage product candidate Revascor. Nasdaq-listed shares of the company rose over 3% by Thursday morning.The biotechnology company is seeking to file an application for the approval of Revascor for the treatment of patients with ischemic chronic heart failure, characterized by an enlarged heart and insufficient blood flow to the organs and extremities of the body. The condition is estimated to affect 2% of the adult population of the United States.During the meeting held in the first week of June, there was general alignment on items regarding chemistry, manufacturing &amp; controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval, the company said.The firm added that it is now awaiting the final minutes from the FDA to determine the timeline for a potential approval filing.The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). Ryoncil is currently approved for the treatment of pediatric patients two months of age and older, and the company is looking to expand the scope of its treatment to adults.On Stocktwits, retail sentiment around Mesoblast rose from ‘neutral’ to ‘bullish’ over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:634/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_10_45_51_AM_png_80e25b67b7.webp" alt="MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits" width="634" height="63"><figcaption>MESO's Sentiment Meter and Message Volume as of 10:45 a.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the update from the company and said that it is at its “inflection point.”<stembedurl>https://stocktwits.com/Mani86/message/617651955</stembedurl><a href="https://stocktwits.com/symbol/MESO">MESO stock</a> is down by about 41% this year but up by nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cardinal-health-raises-fy25-earnings-guidance/chlgGvBRb6x">Cardinal Health’s Improved FY25 Earnings Guidance Draws Retail Cheer, Stock Inches Toward Record Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

Denmark-headquartered Novo Nordisk (NVO) has <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases-302478417.html">entered</a> into a collaboration and exclusive worldwide license agreement with California-based Deep Apple Therapeutics, Inc. to develop drugs for cardiometabolic diseases, including obesity.Under the terms of the deal, valued at up to $812 million, Deep Apple will discover oral therapies using its AI-based drug discovery platform, and Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.Both companies will collaborate on the research plan, Deep Apple said.Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.Last month, Novo also announced a similar exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases. The company said the deal could be worth up to $2.2 billion.Separately, chipmaker Nvidia (NVDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://nvidianews.nvidia.com/news/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery">announced</a> a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development.“By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk.On Stocktwits, retail sentiment around Novo Nordisk jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_10_20_55_AM_png_f4ab145e9d.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 9% this year and about 44% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-slams-fed-for-not-cutting-rates-post-inflation-report/chlaMlyRbCt">JD Vance Slams Fed For Not Cutting Rates Post Inflation Report, Says Refusal By The Central Bank Is ‘Monetary Malpractice’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels

Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.

Autonomous driving technology company WeRide Inc. (WRD) on Tuesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/03/3092549/0/en/WeRide-Teams-Up-with-Renault-to-Bring-Autonomous-Shuttle-to-Roland-Garros-Again.html">said</a> that it is partnering with French automaker Renault Group for the second consecutive year to provide a Level-4 autonomous minibus shuttle service during the 2025 Grand Slam tournament at Stade Roland Garros in Paris, France.WeRide Robobus debuted at the French Open last year.The Robobus service covers 2.8 km in 12 minutes, connecting Avenue de la Porte d'Auteuil, Place de la Porte d'Auteuil, P1 Parking Carrefour des Anciens Combattants, and Village de Roland Garros. It runs daily from May 25 to June 8, 10.30 a.m. to 5 p.m., 6 p.m. to 8 p.m. and 10 p.m. to midnight.WeRide and Renault jointly launched Europe’s first fully driverless commercial Robobus deployment in France’s Drôme region in March, in collaboration with beti Automated Mobility and Macif.WeRide's Robobus is a pre-designed autonomous driving minibus that is powered by the company’s full-stack, self-developed autonomous driving system.The company’s products have received autonomous driving permits in China, the U.A.E., Singapore, France, and the U.S.Last month, WeRide and ride-hailing platform Uber Technologies (UBER) announced plans to expand their autonomous vehicle partnership to 15 additional cities over the next five years, focusing on regions outside the U.S. and China, including Europe.In each new city, WeRide’s autonomous vehicles will operate through the Uber app, with Uber handling fleet operations.Uber also committed to an equity investment of $100 million in WeRide in addition to its existing investment as part of the extended partnership. The investment is expected to be completed by the second half of 2025.On Stocktwits, retail sentiment around WeRide fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_03_at_7_24_25_AM_png_c7d9e6aee6.webp" alt="WRD's Sentiment Meter and Message Volume as of 7:20 a.m. ET on June 3, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>WRD's Sentiment Meter and Message Volume as of 7:20 a.m. ET on June 3, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/WRD">WRD stock</a> is trading about 2% higher in pre-market on Tuesday. The stock is down approximately 31% this year and 41% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/microsoft-cuts-hundreds-of-jobs-amid-inclement-macro-rising-capex-needs/chkrTPERbvB">Microsoft Cuts Hundreds Of Jobs Amid Inclement Macro, Rising AI Capex Needs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the WeRide, Inc. logo is displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

WeRide Partners With Renault To Provide Autonomous Shuttle At The French Open, But Retail’s Not Excited 

The Robobus service covers 2.8 km in 12 minutes, connecting Avenue de la Porte d'Auteuil, Place de la Porte d'Auteuil, P1 Parking Carrefour des Anciens Combattants, and Village de Roland Garros.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

APIE
Trust For Professional Managers - ActivePassive International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest APIE News

APIETrust For Professional Managers - ActivePassive International Equity ETF